Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Analysts Bullish On Crestor After Strong JUPITER Data

This article was originally published in The Pink Sheet Daily

Executive Summary

JPMorgan raises global sales estimate but cautions that AstraZeneca has under-invested in the statin.

You may also be interested in...



Chart: Inside JUPITER's Realm: A Closer Look At The Trial Results

AstraZenenca's JUPITER study pushes the boundaries of the statin class to a new level. The latest large-scale outcomes trial for the statin class, using AstraZenenca's Crestor (rosuvastatin), explores use in a population that has healthy LDL cholesterol levels but with high levels of an inflammation biomarker that predicts future cardiovascular events: high-sensitivity C-reactive protein.

Will JUPITER Change Statin Use?

Positive results from AstraZeneca’s outcomes trial of Crestor have all eyes on whether statin utilization will undergo a paradigm shift.

Will JUPITER Change Statin Use?

Positive results from AstraZeneca’s outcomes trial of Crestor have all eyes on whether statin utilization will undergo a paradigm shift.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS067541

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel